Cannabinoid receptor 1 antagonist treatment induces glucagon release and shows an additive therapeutic effect with GLP-1 agonist in diet-induced obese mice

Canadian Journal of Physiology and Pharmacology

Volumn 92, Issue 12, 2014, Pages 975-983

  Patel, Kartikkumar Navinchandra ^a   Joharapurkar, Amit Arvind ^a   Patel, Vishal ^a   Kshirsagar, Samadhan Govind ^a   Bahekar, Rajesh ^a   Kumar, Brijesh ^a   Jain, Mukul R ^a  

^a ZYDUS RESEARCH CENTRE   (India)

Author keywords

Exendin 4; Hyperglycemia; Insulin; Rimonabant

Indexed keywords

EXENDIN 4; GLUCAGON; GLUCOSE; INSULIN; LEPTIN; RIMONABANT; SACCHARIN; ANTIOBESITY AGENT; CANNABINOID 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 1; GLUCOSE BLOOD LEVEL; PEPTIDE; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE; VENOM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; AVERSION; BEHAVIOR CHANGE; BODY WEIGHT; CONTROLLED STUDY; DIET; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; FOOD INTAKE; FORCED SWIM TEST; GLUCAGON BLOOD LEVEL; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GLUCOSE TOLERANCE TEST; HORMONE BLOOD LEVEL; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INTRAPERITONEAL GLUCOSE TOLERANCE TEST; LONG TERM CARE; MALE; MOUSE; NAUSEA; NONHUMAN; OBESITY; REPEATED DRUG DOSE; SINGLE DRUG DOSE; THERAPY EFFECT; WEIGHT REDUCTION; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DRUG EFFECTS; EATING; INSULIN RESISTANCE; LIPID DIET; METABOLISM; MOUSE MUTANT; PATHOPHYSIOLOGY;

ANIMALS; ANTI-OBESITY AGENTS; BLOOD GLUCOSE; BODY WEIGHT; DIET, HIGH-FAT; DRUG SYNERGISM; EATING; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; INSULIN RESISTANCE; MALE; MICE, INBRED C57BL; MICE, OBESE; OBESITY; PEPTIDES; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; VENOMS;

EID: 84912025825     PISSN: 00084212     EISSN: 12057541     Source Type: Journal    
DOI: 10.1139/cjpp-2014-0310     Document Type: Article

References (46)

1. Ahrén, B., Winzell, M.S., and Pacini, G. 2008. The augmenting effect on insulin secretion by oral versus intravenous glucose is exaggerated by high-fat diet in mice. J. Endocrinol. 197: 181–187. doi:10.1677/JOE-07-0460. PMID:18372244
2. Alhadeff, A.L., Rupprecht, L.E., and Hayes, M.R. 2012. GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake. Endocrinology, 153: 647–658. doi:10.1210/en.2011-1443. PMID:22128031
3. Bermúdez-Silva, F.J., Serrano, A., Diaz-Molina, F.J., Sánchez Vera, I., Juan-Pico, P., Nadal, A., Fuentes, E., et al. 2006. Activation of cannabinoid CB1 receptors induces glucose intolerance in rats. Eur. J. Pharmacol. 531: 282–284. doi:10.1016/j.ejphar.2005.12.016. PMID:16423347
4. Bermúdez-Silva, F.J., Suárez, J., Baixeras, E., Cobo, N., Bautista, D., Cuesta-Muñoz, E., et al. 2008. Presence of functional cannabinoid receptors in human endocrine pancreas. Diabetologia, 51: 476–487. doi:10.1007/s00125-007-0890-y. PMID:18092149
5. Beyer, C.E., Dwyer, J.M., Piesla, M.J., Platt, B.J., Shen, R., Rahman, Z., et al. 2010. Depression-like phenotype following chronic CB1 receptor antagonism. Neurobiol. Dis. 39: 148–155. doi:10.1016/j.nbd.2010.03.020. PMID:20381618
6. Blonde, L., Klein, E.J., Han, J., Zhang, B., Mac, S.M., Poon, T.H., et al. 2006. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes. Metab. 8: 436–447. doi:10.1111/j.1463-1326.2006.00602.x. PMID:16776751
7. Bojanowsk, E., and Radziszewska, E. 2011. Combined stimulation of glucagonlike peptide-1 receptor and inhibition of cannabinoid CB1 receptor act synergistically to reduce food intake and body weight in the rat. J. Physiol. Pharmacol. 62(4): 395–402. PMID:22100840
8. Brunetti, L., Orlando, G., Recinella, L., Leone, S., Ferrante, C., Chiavaroli, A., et al. 2008. Glucagon-like peptide 1 (7-36) amide (GLP-1) and exendin-4 stimulate serotonin release in rat hypothalamus. Peptides, 29(8): 1377–1381. doi:10.1016/j.peptides.2008.04.007. PMID:18502539
9. Christensen, R., Kristensen, P.K., Bartels, E.M., Bliddal, H., and Astrup, A. 2007. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet, 370(9600): 1706–1713. doi:10.1016/S0140-6736(07)61721-8. PMID:18022033
10. Cristino, L., Becker, T., and Di Marzo, V. 2014. Endocannabinoids and energy homeostasis: an update. Biofactors, 40(4): 389–397. doi:10.1002/biof.1168. PMID:24752980
11. Day, J.W., Ottaway, N., Patterson, J.T., Gelfanov, V., Smiley, D., Gidda, J., et al. 2009. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat. Chem. Biol. 5(10): 749–757. doi:10.1038/nchembio.209. PMID:19597507
12. Despres, J.P., Golay, A., and Sjostrom, L. 2005. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N. Engl. J. Med. 353(20): 2121–2134. doi:10.1056/NEJMoa044537. PMID:16291982
13. Di Marzo, V., and Matias, I. 2005. Endocannabinoid control of food intake and energy balance. Nat. Neurosci. 8(5): 585–589. doi:10.1038/nn1457. PMID:15856067
14. Diehl, K.H., Hull, R., Morton, D., Pfister, R., Rabemampianina, Y., Smith, D., et al. 2001. A Good Practice Guide to the Administration of Substances and Removal of Blood, Including Routes and Volumes. J. Appl. Toxicol. 21: 15–23. doi:10.1002/jat.727. PMID:11180276
15. Drucker, D.J., Philippe, J., Mojsov, S., Chick, W.L., and Habener, J.F. 1987. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc. Natl. Acad. Sci. U.S.A. 84: 3434–3438. doi:10.1073/pnas.84.10.3434. PMID:3033647
16. Ebert, R., and Creutzfeldt, W. 1987. Gastrointestinal peptides and insulin secretion. Diabetes Metab. Rev. 3: 1–16. doi:10.1002/dmr.5610030101. PMID:3552520
17. Ezcurra, M., Reimann, F., Gribble, F.M., and Emery, E. 2013. Molecular mechanisms of incretin hormone secretion. Curr. Opin. Pharmacol. 13(6): 922–927. doi:10.1016/j.coph.2013.08.013. PMID:24035446
18. Flores, L.E., Alzugaray, M.E., Cubilla, M.A., Raschia, M.A., Del Zotto, H.H., Román, C.L., et al. 2013. Islet cannabinoid receptors: cellular distribution and biological function. Pancreas, 42(7): 1085–1092. doi:10.1097/MPA.0b013e31828fd32d. PMID:24005231
19. Folli, F., and Guardado Mendoza, R. 2011. Potential use of exenatide for the treatment of obesity. Expert Opin. Investig. Drugs, 20(12): 1717–1722. doi:10.1517/13543784.2011.630660. PMID:22017240
20. Gentilella, R., Bianchi, C., Rossi, A., and Rotella, C.M. 2009. Exenatide: a review from pharmacology to clinical practice. Diabetes Obes. Metab. 11(6): 544–556. doi:10.1111/j.1463-1326.2008.01018.x. PMID:19383034
21. Getty-Kaushik, L., Richard, A.M., Deeney, J.T., Krawczyk, S., Shirihai, O., and Corkey, B.E. 2009. The CB1 Antagonist Rimonabant Decreases Insulin Hypersecretion in Rat Pancreatic Islets. Obesity (Silver Spring), 17(10): 1856–1860. doi:10.1038/oby.2009.234. PMID:19644453
22. Habegger, K.M., Heppner, K.M., Geary, N., Bartness, T.J., DiMarchi, R., and Tschop, M.H. 2010. The metabolic actions of glucagon revisited. Nat. Rev. Endocrinol. 6(12): 689–697. doi:10.1038/nrendo.2010.187. PMID:20957001
23. Isacson, R., Nielsen, E., Dannaeus, K., Bertilsson, G., Patrone, C., Zachrisson, O., and Wikström, L. 2011. The glucagon-like peptide 1 receptor agonist exendin-4 improves reference memory performance and decreases immobility in the forced swim test. Eur. J. Pharmacol. 650(1): 249–255. doi:10.1016/j.ejphar.2010.10.008. PMID:20951130
24. James, W.P. 2008. The epidemiology of obesity: the size of the problem. J. Intern. Med. 263(4): 336–352. doi:10.1111/j.1365-2796.2008.01922.x. PMID:18312311
25. Kim, W., Doyle, M.E., Liu, Z., Lao, Q., Shin, Y.K., Carlson, O.D., et al. 2011. Cannabinoids inhibit insulin receptor signaling in pancreatic beta-cells. Diabetes, 60(4): 1198–1209. doi:10.2337/db10-1550. PMID:21346174
26. Kirilly, E., Gonda, X., and Bagdy, G. 2012. CB1 receptor antagonists: new discoveries leading to new perspectives. Acta Physiol. (Oxf.), 205(1): 41–60. doi:10.1111/j.1748-1716.2011.02402.x. PMID:22463610
27. Kopelman, P.G. 2000. Obesity as a medical problem. Nature, 404(6778): 635–643. doi:10.1038/35007508. PMID:10766250
28. Li, C., Bowe, J.E., Huang, G.C., Amiel, S.A., Jones, P.M., and Persaud, S.J. 2011. Cannabinoid receptor agonists and antagonists stimulate insulin secretion from isolated human islets of Langerhans. Diabetes Obes. Metab. 13(10): 903–910. doi:10.1111/j.1463-1326.2011.01422.x. PMID:21564460
29. Liang, N.C., Bello, N.T., and Moran, T.H. 2013. Additive feeding inhibitory and aversive effects of naltrexone and exendin-4 combinations. Int. J. Obes. (Lond.), 37(2): 272–278. doi:10.1038/ijo.2012.16. PMID:22310470
30. Liu, J., Zhou, L., Xiong, K., Godlewski, G., Mukhopadhyay, B., Tam, J., et al. 2012. Hepatic cannabinoid receptor-1 mediates diet-induced insulin resistance via inhibition of insulin signaling and clearance in mice. Gastroenterology, 142(5): 1218–1228. doi:10.1053/j.gastro.2012.01.032. PMID:22307032
31. Mandhane, S., Nayak, P., Soni, D., Jain, S., Ashton, J.C., and Rajamannar, T. 2012. Induction of glucose intolerance by acute administration of rimonabant. Pharmacology, 89(5–6): 339–347. doi:10.1159/000337731. PMID:22678147
32. Norgren, R., Grigson, P., Hajnal, A., and Lundy, R.F.J. 2003. Motivational modulation of taste. In Limbic and Association Cortical Systems: Basic, Clinical and Computational Aspects. Edited by T. Ono, G. Matsumoto, R. Llinas, et al. Elsevier Science, Amsterdam, the Netherlands. pp. 319–334
33. Patel, V., Joharapurkar, A., Dhanesha, N., Kshirsagar, S., Patel, K., Bahekar, R., et al. 2013. Co-agonist of glucagon and GLP-1 reduces cholesterol and improves insulin sensitivity independent of its effect on appetite and body weight in diet-induced obese C57 mice. Can. J. Physiol. Pharmacol. 91(12): 1009–1015. doi:10.1139/cjpp-2013-0189. PMID:24289070
34. Perfetti, R., and Merkel, P. 2000. Glucagon-like peptide-1: a major regulator of pancreatic beta-cell function. Eur. J. Endocrinol. 143: 717–725. doi:10.1530/eje.0.1430717. PMID:11124853
35. Pi-Sunyer, F.X., Aronne, L.J., Heshmati, H.M., Devin, J., and Rosenstock, J. 2006. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA, 295(7): 761–775. doi:10.1001/jama.295.7.761. PMID:16478899
36. Pocai, A., Carrington, P.E., Adams, J.R., Wright, M., Eiermann, G., Zhu, L., et al. 2009. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes, 58(10): 2258–2266. doi:10.2337/db09-0278. PMID:19602537
37. Ravinet Trillou, C., Arnone, M., Delgorge, C., Gonalons, N., Keane, P., Maffrand, J.P., et al. 2003. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet induced obese mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 284: R345–R353. doi:10.1152/ajpregu.00545.2002. PMID:12399252
38. Rohrbach, K., Thomas, M.A., Glick, S., Fung, E.N., Wang, V., Watson, L., et al. 2012. Ibipinabant attenuates beta-cell loss in male Zucker diabetic fatty rats independently of its effects on body weight. Diabetes Obes. Metab. 14(6): 555–564. doi:10.1111/j.1463-1326.2012.01563.x. PMID:22268426
39. Rosenzweig-Lipson, S., Beyer, C.E., Hughes, Z.A., Khawaja, X., Rajarao, S.J., Malberg, J.E., et al. 2007. Differentiating antidepressants of the future: efficacyandsafety. Pharmacol. Ther. 113: 134–153. doi:10.1016/j.pharmthera.2006.07.002. PMID:17010443
40. Silvestre, R.A., Rodríguez-Gallardo, J., Egido, E.M., and Marco, J. 2003. Interrelationship among insulin, glucagon and somatostatin secretory responses to exendin-4 in the perfused rat pancreas. Eur. J. Pharmacol. 469(1–3): 195–200. doi:10.1016/S0014-2999(03)01692-3. PMID:12782202
41. Sisley, S., Gutierrez-Aguilar, R., Scott, M., D’Alessio, D.A., Sandoval, D.A., and Seeley, R.J. 2014. Neuronal GLP1R mediates liraglutide’s anorectic but not glucose-lowering effect. J. Clin. Invest. 124(6): 2456–2463. doi:10.1172/JCI72434. PMID:24762441
42. Tam, J., Vemuri, V.K., Liu, J., Batkai, S., Mukhopadhyay, B., Godlewski, G., et al. 2010. Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J. Clin. Invest. 120: 2953–2966. doi:10.1172/JCI42551. PMID:20664173
43. Tzavara, E.T., Davis, R.J., Perry, K.W., Li, X., Salhoff, C., Bymaster, F.P., et al. 2003. The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions. Br. J. Pharmacol. 138(4): 544–553. doi:10.1038/sj.bjp.0705100. PMID:12598408
44. Vickers, S.P., Webster, L.J., Wyatt, A., Dourish, C.T., and Kennett, G.A. 2003. Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats. Psychopharmacology (Berl.), 167(1): 103–111. doi:10.1007/s00213-002-1384-8. PMID:12632249
45. Wosko, S., Serefko, A., Soca, A.K., Szewczyk, B., Wróbel, A., Nowak, G., et al. 2014. An anti-immobility effect of spermine in the forced swim test in mice. Pharmacol. Rep. 66(2): 223–227. doi:10.1016/j.pharep.2013.10.002. PMID:24911073
46. Young, A.A., Gedulin, B.R., Bhavsar, S., Bodkin, N., Jodka, C., Hansen, B., and Denaro, M. 1999. Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes, 48(5): 1026–1034. doi:10.2337/diabetes.48.5.1026. PMID:10331407